CRDF - Cardiff Oncology up 12% on phase 2 data for pancreatic cancer candidate
2023-09-26 17:05:11 ET
More on Cardiff Oncology
- Cardiff Oncology: How The Recommitment Shapes The Investment Thesis (Rating Upgrade)
- Cardiff Oncology soars as Pfizer backs lead program
- Seeking Alpha's Quant Rating on Cardiff Oncology
For further details see:
Cardiff Oncology up 12% on phase 2 data for pancreatic cancer candidate